Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.
April 9, 2019 at 12:29 PM EDT
MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) — Clementia Pharmaceuticals Inc.(Nasdaq: CMTA) (“Clementia” or the “Corporation”) is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to which a wholly-owned subsidiary of Ipsen S.A. will acquire all of the issued and outstanding common shares of Clementia for US$25.00 per share in cash upfront on completion of the transaction plus a deferred payment on the achievement of a future regulatory milestone in the form of a contingent value right of US$6.00 per share payable upon the U.S. Food and Drug Administration’s (FDA) acceptance of submission of a new drug application (NDA) filing for palovarotene for the treatment of multiple osteochondromas (MO) on or prior to December 31, 2024.
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen to acquire Epizyme, expanding its portfolio in oncology
Ipsen Completes Acquisition of Clementia Pharmaceuticals